Cytokines in viral hepatitis

Seminars in Liver Disease

Volumn 19, Issue 2, 1999, Pages 157-170

  Koziel, Margaret James ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Cytokines; Hepatitis B; Hepatitis C

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 4;

CYTOKINE PRODUCTION; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; LIVER INJURY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

EID: 0032765992     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007107     Document Type: Review

References (147)

1. Foster GR. Interferons in host defense. Semin Liver Dis 1997; 17:287-295
2. Peters M. Actions of cytokines on the immune response and viral interactions: An overview. Hepatology 1996;23:909-916
3. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: Structure and function. J Interferon Cytokine Res 1997;17:503-524
4. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991;183:1-11
5. Attallah AM, Strong DM. Differential effects of interferon on the MHC expression of human lymphocytes. Enhanced expression of HLA without effect on Ia. Int Arch Allergy Appl Immunol 1979;60:101-105
6. Bukowski JF, Woda BA, Habu S, et al. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 1983;131:1531-1538
7. Trinchieri G, Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol 1997;9:17-23
8. Orange JS, Wolf SF, Biron CA. Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 1994;152:1253-1264
9. de Martino M, Rossi ME, Muccioli AT, et al. Interference of hepatitis B virus surface antigen with natural killer cell function. Clin Exp Immunol 1985;61:90-95
10. Corado J, Toro F, Rivera H, et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997;109:451-457
11. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 1996;17:138-146
12. Biron CA. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 1994;6: 530-538
13. Tough DF, Borrow P, Spent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-1950
14. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715-1728
15. + T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol 1997;159:2240-2249
16. Unutmaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 1994;180:1159-1164
17. + T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989;112:161-182
18. Urban JF Jr, Katona IM, Paul WE, Finkelman FD. Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. Proc Natl Acad Sci USA 1991;88: 5513-5517
19. Daugelat S, Kaufmann SH. Role of Th1 and Th2 cells in bacterial infections. Chem Immunol 1996;63:66-97
20. Cenci E, Mencacci A, Del Sero G, et al. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 atagonist. J Infect Dis 1997;176:217-226
21. Spaccapelo R, Del Sero G, Mosci P, et al. Early T cell unresponsiveness in mice with candidiasis and reversal by IL-2: Effect on T helper cell development. J Immunol 1997;158:2294-2302
22. Matyniak JE, Reiner SL. T helper phenotype and genetic susceptibility in experimental Lyme disease. J Exp Med 1995;181: 1251-1254
23. Gotch F, Gallimore A, McMichael A. Cytotoxic T cells - Protection from disease progression - Protection from infection. Immunol Lett 1996;51:125-128
24. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997;4:32-40
25. Nakamoto Y, Guidotti LG, Pasquetto V, et al. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997;158:5692-5697
26. Pasternack MS, Bevan MJ, Klein JR. Release of discrete interferons by cytotoxic T lymphocytes in response to immune and nonimmune stimuli. J Immunol 1984;133:277-280
27. Merrill JE, Ellison GW, Myers LW. Cytotoxic activity of peripheral blood and cerebrospinal fluid lymphocytes from patients with multiple sclerosis and other neurological diseases: Analysis at the single cell level of the relationship of cytotoxic effectors and interferon-producing cells. Clin Immunol Immunopathol 1984;31:390-402
28. Koziel MJ, Dudley D, Afdhal N, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321
29. Kagi D, Vignaux F, Ledermann B, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-530
30. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993;259: 1742-1745
31. Wille A, Gessner A, Lother H, Lehmann-Grube F. Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elmination. Eur J Immunol 1989;19:1283-1288
32. Moskophidis D, Battegay M, Bruendler MA, et al. Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon. J Virol 1994;68:1951-1955
33. Ramshaw IA, Ramsay AJ, Karupiah G, et al. Cytokines and immunity to viral infections. Immunol Rev 1997;159:119-135
34. Graham MB, Dalton DK, Giltinan D, et al. Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J Exp Med 1993;178:1725-1732
35. Kagi D, Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996;8:472-477
36. Von Herrath MG, Coon B, Oldstone MB. Low-affinity cytotoxic T-lymphocytes require IFN-gamma to clear an acute viral infection. Virol 1997;229:349-359
37. + T cell can give rise to progeny expressing type 1 and/or type 2 cytokine genes and can retain its multipotentiality through many cell divisions. Proc Natl Acad Sci USA 1997;94:8070-8075
38. Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997;112:193-199
39. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251
40. Baumgarth N, Egerton M, Kelso A. Activated T cells from draining lymph nodes and an effector site differ in their responses to TCR stimulation. J Immunol 1997;159:1182-1191
41. Milich DR, Peterson DL, Schodel F, et al. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J Virol 1995;69:2776-2785
42. Smith GL. Virus proteins that bind cytokines, chemokine, or interferons. Curr Opin Immunol 1996;8:467-471
43. Spriggs MK, Hruby DE, Maliszewski CR, et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 1992;71:145-152
44. Upton C, Mossman K, McFadden G. Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science 1992;258: 1369-1372
45. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337; 1733-1745
46. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
47. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18:339-347
48. Milich DR, Sallberg M, Maruyama T. The humoral immune response in acute and chronic hepatitis B virus infection. Springer Semin Immunopathol 1995;17:149-166
49. Ferrari C, Bertolelli A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88:214-222
50. Milich DR, McLachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987;329: 547-549
51. Milich DR, McLachlan A, Stahl S, et al. Comparative immunogenicity of hepatitis B virus core and E antigens. J Immunol 1988;141:3617-3624
52. Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174: 1565-1570
53. Nayersina R, Fowler P, Giulhot S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4659-4671
54. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-1477
55. Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997;25: 1022-1027
56. Rossol S, Marinos G, Carucci P, et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997;99:3025-3033
57. Thursz MR, Kwiatkowski D, Allsopp CE, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-1069
58. Höhler T, Gerken G, Notghi A, et al. HLA DRB* 1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997;26:503-507
59. Milich DR, Schodel F, Hughes JL, et al. The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype. J Virol 1997;71:2192-2201
60. Penna A, Fowler P, Bertoletti A, et al. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: Characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J Virol 1992;66: 1193-1198
61. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-1058
62. Eddleston ALWF, Mondelli M, Mieli-Vergani G, Williams R. Lymphocyte cytotoxic to autologous hepatocytes in chronic hepatitis B virus infection. Hepatology 1982;2(suppl): 122-127S
63. Guidotti LG, Chisari FV. To kill or to cure: Options in host defense against viral infection. Curr Opin Immunol 1996;8: 478-483
64. Ando K, Guidotti LG, Cerny A, et al. CTL access to tissue antigen is restricted in vivo. J Immunol 1994;153:482-488
65. Gilles PN, Guerrette DL, Ulevitch RJ, et al. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatol 1992;16:655-663
66. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA 1995; 92:12398-12402
67. Romero R, Lavine JE. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology 1996;23:17-23
68. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994;91:3764-3768
69. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36
70. Zinkernagel R, Haensler E, Lcist C, et al. Cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis. J Exp Med 1986;164:1075-1092
71. Guidotti LG, Borrow P, Hobbs MV, et al. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996;93:4589-4594
72. Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 1998;72:2630-2637
73. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997;71:3236-3243
74. Barnaba V, Franco A, Aiberti A, et al. Recognition of hepatitis B virus envelope proteins by liver-infiltrating lymphocytes in chronic HBV infection. J Immunol 1989;143:2650-2655
75. Lohr HF, Gerken G, Schlicht HJ, et al. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993;168:1133-1139
76. Dienes H, Hutteroth T, Hess G, Meuer S. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology 1987;7: 1317-1325
77. Moriyama T, Guilhot S, Klopchin K, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248:361-364
78. Ando K, Moriyama T, Guidotti L, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178:1541-1554
79. Toyonaga T, Hipo O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-γin the liver. Proc Natl Acad Sci USA 1994;91:614-618
80. Guilhot S, Miller T, Cornman G, Isom HC. Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus. Am J Pathol 1996;148:801-814
81. Orange J, Salazar-Mather T, Opal S, Biron C. Mechanisms for virus-induced liver disease: Tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 1997;71:9248-9258
82. Ando K, Hiroishi K, Kaneko T, et al. Perform, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997;158:5283-5291
83. Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am 1998;12:13-26
84. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepatitis 1997;4(suppl 2): 31-41
85. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994;19:286-295
86. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346.1006-1007
87. Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al. T-and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C virus infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996;24:790-795
88. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-714
89. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995;21:632-638
90. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587
91. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997;71:6011-6019
92. + T cells specific for the protien NS4 of hepatitis C virus in patients with the chronic hepatitis C. J Exp Mcd 1993;178:17-25
93. Rehermann B, Takaki A, Liebtrau A, et al. Characterization of the cytotoxic and helper T cell response in patients eighteen years after a single source outbreak of HCV infection. Hepatology 1997;26:A1109
94. Koziel MJ, Dudley D, Wong J, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344
95. Nelson DR, Marousis CG, Davis G, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481
96. Rehermann B, Chang KM, McHutchinson J, et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996;98:1431-1440
97. Koziel M, Walker B. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997;19:69-84
98. Wong D, Dudley D, Afdhal N, et al. Liver-derived cytotoxic T lymphocytes in hepatitis C virus infection: Breadth and specificity of responses in persons with chronic hepatitis. J Immunol 1998;160:1479-1488
99. Tsai SL, Liaw YF, Chen MH, et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for Hepatitis C virus chronicity. Hepatology 1997;25:449-458
100. Woitas RP, Lechmann M, Jung G, et al. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997;159:1012-1018
101. Kakumu S, Okumura A, Ishikawa T, et al. Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997;109:458-463
102. Kuzushita N, Hayashi N, Katayama K, et al. Fusamoto H. High levels of serum interleukin-10 are associated with a poor response to inteferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997;32:169-174
103. Rieser M, Marousis CG, Nelson DR, et al. Serum interleukin 4 and interleukin 10 levels in patietns with chronic hepatitis C virus infection. J Hepatol 1997;26:471-478
104. Maggi F, Fornai C, Vatteroni ML, et al. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J Gen Virol 1997; 78:1521-1525
105. + T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 1998;28:3448-3455
106. Lamonoca V, Pilli M, Missale G, et al. Functional characterization of intrahepatic HCV-specific HLA class II restricted T cells in chronic hepatitis C. In: Fifth International Conference on Hepatitis C and Related Flaviviruses. Venice, 1998:Abstract O46
107. + surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol 1994;152:3074-3087
108. Imawari M, Nomura M, Kaieda T. Establishment of a human T cell clone cytotoxic for both autologous and allogeneic hepatocytes from chronic hepatitis patients with type non-A, non-B virus. Proc Natl Acad Sci USA 1989;86:2883-2887
109. Jin Y, Fuller L, Carreno M, et al. The immune reactivity role of HCV-induced liver infiltrating lympocytes in hepatocellular damage. J Clin Immunol 1997;17:140-153
110. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994;55:97-179
111. Kurilla MG, Swaminathan S, Welsch RM, et al. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J Virol 1993;67:7623-7628
112. Dumoulin FL, Bach A, Leifeld L, et al. Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. J Infect Dis 1997;175:681-685
113. Llorent L, Richaud-Patin Y, Alcocer-Castillejos N, et al. Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J Hepatol 1996;24:555-563
114. Napoli J, Bishop GA, McCaughan GW. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology 1994;107:789-798
115. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-765
116. Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996;16:390-399
117. Martin S, Kohler H, Weltzien HU, Leipner C. Selective activation of CD8 T cell effector functions by epitope variants of lymphocytic choriomeningitis virus glycoprotien. J Immunol 1996;157:2358-2365
118. Ando K, Guidotti L, Wirth S, et al. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994;152:3245-3253
119. Roulot D, Durand H, Coste T, et al. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease. Hepatology 1995; 21:298-304
120. Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996;49:998-1004
121. Chen RH, Chang TY. Involvement of caspase family proteases in transforming growth factor-beta-induced apoptosis. Cell Growth Diff 1997;8:821-827
122. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995;22:28-36
123. Kanto T, Takehara T, Katayama K, et al. Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro. J Clin Immunol 1997;17:462-471
124. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-253
125. Kitajewski J, Schneider RJ, Safer B, et al. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 1986;45:195-200
126. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993;11:165-190
127. Twu JS, Lee CH, Lin PM, Schloemer RH. Hepatitis B virus suppresses expression of human beta-interferon. Proc Natl Acad Sci USA 1988;85:252-256
128. Foster GR, Ackrill AM, Goldin RD, et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA [published erratum appears in Proc Natl Acad Sci USA 1995;92:3632]. Proc Natl Acad Sci USA 1991;88:2888-2892
129. Natoli G, Avantaggiati ML, Chirillo P, et al. Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX. J Hetapol 1995;22:14-20
130. Mahe Y, Mukaida N, Kuno K, et al. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 1991;266:13759-13763.
131. Fiedler MA, Werke-Dollries K, Stark JM. Mechanism of RSV-induced IL-8 gene expression in A549 cells before viral replication. Am J Physiol 1996;271:L963-971
132. Fiedler MA, Wernke-Dollries K, Stark JM. Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am J Physiol 1995;269:L865-872
133. Murayama T, Ohara Y, Obuchi M, et al. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1-and NF-kappaB-binding sites of the interleukin-8 gene. J Virol 1997;71: 5692-5695
134. Khabar KS, Al-Zoghaibi F, Al-Ahdal MN, et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 1997;186:1077-1085
135. Oshikawa O, Tamura S, Kawata S, et al. The effect of hepatitis B virus X gene expression on response to growth inhibition by transforming growth factor-beta 1. Biochem Biophys Res Commun 1996;222:770-773
136. Wold WS. Adenovirus genes that modulate the sensitivity of virus-infected cells to lysis by TNF. J Cell Biochem 1993;53: 329-335
137. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997;94:8744-8749
138. Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem 1998;273:381-385
139. Nakamura K, Yuh K, Sugyo S, et al. Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996;111:156-164
140. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997;229:68-76
141. Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998;72:3691-3697
142. Lerat H, Berby F, Trabaud MA, et al. Specific detection of hepatitis C virus minus strand RNA in hemalopoielic cells. J Cells Invest 1996;97:845-851
143. Carithers RL, Emerson S. Therapy of hepatitis C: Meta-analysis of interferon alpha-2b trials. Hepatology 1997:26(suppl 1) 83S-88S
144. Podevin P, Guechot J, Serfaty L, et al. Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients. J Hepatol 1997;27:265-271
145. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81
146. Gale MJ Jr, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-227
147. Heim MH, Moradpur D, Blum H. Expression of hepatitis C virus proteins inhibits interferon-alpha induced signaling through the Jak-STAT pathway. In: Fifth International Conference on Hepatitis C and Related Flaviviruses, Venice, 1998:Abstract O58